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ABSTRACT: Resolution of inflammation is poorly understood inAchilles tendon disorders. Herein, we investigated
the bioactive lipid mediator profiles of tendon-derived stromal cells isolated from patients with Achilles tendin-
opathy (AT) or Achilles rupture (AR) under baseline and IL-1b–stimulated conditions. We also determined
whether incubating these cellswith2of themediatorsproducedby tendon-derivedstromal cells, 15-epi-LipoxinA4
(15-epi-LXA4) or maresin (MaR)-1, moderated their proinflammatory phenotype. Under baseline conditions,
AT cells showed concurrent increased levels of proinflammatory eicosanoids and proresolving mediators com-
pared with AR cells. IL-1b treatment induced profound prostaglandin E2 release in AR compared with AT cells.
Incubation of IL-1b treated AT and AR tendon-derived stromal cells in 15-epi-LXA4 or MaR1 reduced proin-
flammatory eicosanoids and potentiated the release of proresolving mediators. These mediators also induced
specialized proresolving mediator (SPM) biosynthetic enzymes arachidonate lipoxygenase (ALOX) 12 and
ALOX15 and up-regulated the proresolving receptor ALX compared with vehicle-treated cells. Incubation in
15-epi-LXA4 orMaR1 alsomoderated the proinflammatory phenotype ofAT andAR cells, regulating podoplanin,
CD90, signal transducer and activator of transcription (STAT)-1, IL-6, IFN regulatory factor (IRF) 5, and TLR4 and
suppressed c-Jun N-terminal kinase 1/2/3, Lyn, STAT-3, and STAT-6 phosphokinase signaling. In summary, we
identifyproresolvingmediators thatareactive inATandARandproposeSPMs, including15-epi-LXA4orMaR1, as
apotential strategy to counterregulate inflammatoryprocesses in these cells.—Dakin, S.G.,Colas,R.A.,Newton, J.,
Gwilym, S., Jones, N., Reid, H. A. B., Wood, S., Appleton, L., Wheway, K., Watkins, B., Dalli, J., Carr, A. J. 15-Epi-
LXA4 and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture.
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KEY WORDS: resolution • tendon • 15-epi-LipoxinA4 • maresin-1
Achilles tendinopathy (AT) and Achilles rupture (AR) are
common causes of pain and disability affecting ath-
letes and nonathletic patients (1). These injuries require
prolonged rehabilitation and have high rates of recurrent
injury, and their pathology is frequently bilateral (2, 3).
Current advocated therapies for AT include a standard
3-mo eccentric training program (4) and nonsteroidal anti-
inflammatory drugs (NSAIDs) (5, 6). Patients with
persistent tendinopathy are treated with a variety of
therapies, including dry needling, local infiltration
of platelet-rich plasma, high-volume injection (HVI),
glyceryl trinitrate, or surgery (7–11). The lack of high-
quality, multicenter, randomized placebo-controlled
clinical trials hinders the ability to determine which, if
any, of these therapies are clinically effective. Of im-
portance, many of these therapies do not address the
pathobiology associated with AT. Furthermore, cyclo-
oxygenase 2–selective NSAIDs dampen protective
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responses regulating the resolution of inflammation (12,
13), paradoxically impeding the ability of inflamed
tendons to heal. Some patients develop AR and are
managed surgically or conservatively with immobili-
zation and subsequent physical therapy (14). A recent
meta-analysis showed that operative treatment reduced
the risk of rerupture compared with nonoperative
treatment, highlighting that management should be
tailored toward patient-specific factors and shared de-
cision making (15).
The etiology of Achilles tendon disease is complex and
multifactorial and includes the effects of exercise overuse,
aging, and genetic factors (16–18). The importance and
role of inflammation in the disease of these energy-storing
tendons has been highly debated, and historically, the
disease was frequently described as degenerative (19, 20).
More recent studies highlight a paradigm shift toward
improved understanding of inflammatory processes in
Achilles tendon disorders whereby immune-competent
cells including macrophages, T cells, NK, and mast cells
have been identified in patient biopsy specimens (21, 22).
Werecently identified chronic inflammation as a feature of
midportion AT and AR. Tendinopathic and ruptured
Achilles showed complex tissue inflammation signatures
involvingNF-kB, IFN, and signal transducer andactivator
of transcription (STAT)-6 activation pathways. IFN
markers IFN regulatory factor (IRF) 1 and IRF5 were
highly expressed in tendinopathic samples, whereas rup-
tures showed increased prostaglandin-endoperoxide
synthase 2 and IL-8 mRNA expression (22). These differ-
ences in proinflammatory profileswere attributed to acute
inflammation and increased vascularization arising from
the event of traumatic rupture. Of importance, resident
stromal fibroblasts (tendon-derived stromal cells), which
constitute the majority cell type in Achilles tendons, and
their roles in sustaining chronic inflammation remain
underinvestigated.We recently identified tissues and cells
isolated from patients with tendinopathic and ruptured
Achilles that showed a proinflammatory phenotype,
expressing markers of stromal fibroblast activation in-
cluding podoplanin (PDPN) and CD106 (VCAM-1) (22).
In functionally distinct positional tendons, we also iden-
tified tendon-derived stromal cells from patients with
shoulder tendon tears that showed dysregulated resolu-
tion responses compared with cells isolated from the ten-
dons of healthy volunteers (23).
To date, resolution of inflammation has not been in-
vestigated in Achilles tendon disorders. The current study
was performed to advance understanding of resolution
processes active in human AT and AR. This study has 2
main objectives: first, to investigate if tendon stromal cells
isolated from patients with AT and AR show distinct
bioactive lipid mediator (LM) profiles in order to assess
whether inflammation-resolution mechanisms are differ-
entially activated in these distinct conditions; and second,
to identify new therapeutic approaches to counter in-
flammation and potentiate resolution in patient-derived
Achilles tendon stromal cells. We demonstrate that cells
isolated from patients with AT and AR show distinct
bioactive LM profiles. Through experiments with repre-
sentative specialized proresolving mediators (SPMs)
15-epi-Lipoxin A4 (15-epi-LXA4) and maresin (MaR) 1,
we provide evidence that these SPMs regulate the proin-
flammatory phenotype and promote resolution responses
in patient-derived Achilles tendon stromal cells.
MATERIALS AND METHODS
Study approval
Tissues from patients with AT or AR were collected under the
Office for Research Ethics Committees from Northern Ireland
Research Ethics Committee (reference 14/NI/1063). Full in-
formed consent according to the Declaration of Helsinki was
obtained from all patients.
Collection of patient Achilles tendon tissues
PatientswithATwere recruited fromasportsmedicine clinic (n=
15). This group comprised 7 female and 8 male patients aged
between 41 and 65 yr. Patients presenting to the sports clinic had
been symptomatic for severalmonths and failed a standard3-mo
eccentric training program for AT. Ultrasonography was per-
formed to confirm a diagnosis of AT. Patients completed the
Victorian Institute of SportsAssessment–Achilles scoring system
(24), a validated clinical outcomemeasure scoring from 0 (severe
disease) to 100 (normal function). AT biopsies were collected
frompatients thatpresented forHVI, as thisprocedurerepresents
the next step in standard treatment after failed response to
physical therapy. This procedure involves injecting 10 ml 0.5%
bupivacaine and 30 ml saline into the pre-Achilles space. AT
biopsies were obtained via percutaneous ultrasound-guided bi-
opsy under local anesthesia prior to HVI by inserting a 14-gauge
Tru-Cut biopsy needle (Merit Medical Systems, South Jordan,
UT, USA) into the diseased midportion of the Achilles. This
validatedbiopsy technique is previouslydescribedbyDakin et al.
(22). Tissue biopsy samples were also collected from 15 patients
recruited from a trauma unit with acute traumatic AR. This
group comprised 4 female and 11male patients aged between 25
and 60 yr. Tissue biopsy samples were collected up to 48 h after
tendon rupture. Full informed consent according to the Decla-
ration of Helsinki was obtained from all patients participating in
the study. Study exclusion criteria included previous corticoste-
roid,platelet-richplasma, andstemcell intratendinous injections,
extracorporeal shockwave therapy, or systemic steroid or meth-
otrexate treatments. Patients who were diabetic and those re-
ceiving systemic anticoagulant therapywere also excluded from
the study. AT patients did not receive anti-inflammatory medi-
cationsduring their rehabilitation or at the timeof tendonbiopsy.
It was not possible to determine the anti-inflammatory medica-
tions received by all AR patients in this study.
Isolation and cytokine treatment of Achilles
tendon–derived stromal cells
Patient-derived AT or AR tendon stromal cells have been pre-
viously described as CD45negCD34neg cells exhibiting fibroblast-
like morphology (22). Cells were isolated from patient tissues
using previously described protocols (25, 26), and passage 1–2
cells were used for all experiments. Cells were grown until 80%
confluence prior to cytokine stimulation. IL-1b is known to in-
duce expression of NF-kB target genes highly expressed in
Achilles tendon disease (22). To recapitulate this inflammatory
milieu, we therefore investigated the bioactive LM profiles in
tendon-derived stromal cells derived fromATandARpatients in
the presence of IL-1b (10 ng/ml; MilliporeSigma, Burlington,
MA, USA) in medium (DMEM F12 phenol red–free medium;
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Thermo Fisher Scientific, Waltham, MA, USA) containing 1%
heat-inactivated human serum (MilliporeSigma) and 1%
penicillin-streptomycin. Nontreated (vehicle only) cells served as
experimental controls. After cytokine and vehicle treatment, cells
were incubated at 37°C and 5% CO2 for 24 h until experimental
harvest of the medium and lysate for bioactive LM profiling.
Modulating bioactive LM profiles of
IL-1b–stimulated Achilles tendon–derived
stromal cells with 15-epi-LXA4 or MaR1
Cells derived fromATorARpatientswere seeded at a density of
60,000 cells per well. Once cells were 80% confluent, they were
preincubatedwith 10 nM15-epi-LXA4 (CaymanChemicals,Ann
Arbor,MI, USA) or 10 nMMaR1 (CaymanChemicals) for 24 h in
DMEM F12 phenol red–free medium containing 1% heat-
inactivated human serum and 1% penicillin-streptomycin. Cells
were stimulated with IL-1b (10 ng/ml) in the presence of me-
dium containing either 15-epi-LXA4, MaR1, or vehicle control as
previously described (23). Parallel experiments were conducted,
and cell lysateswereharvested to investigatewhether incubating
cells in 15-epi-LXA4 or MaR1 modulated expression of proin-
flammatoryor proresolvinggenes expressedbyATandARcells.
The concentration and integrity of mediators used for these in-
cubations were validated using UV-spectrophotometry and liq-
uid chromatography–tandem mass spectrometry in accordance
with previously published criteria (27, 28).
Bioactive LM profiling of Achilles tendon stromal
cell incubations
We utilized targeted LM profiling that identifies mediators from
all 4majorbioactivemetabolomes, including thearachidonicacid
metabolome, the eicosapentaenoic acid metabolome, the n-3
docosapentaenoic acid (DPA) metabolome, and the docosahex-
aenoic acid metabolome, simultaneously measuring the sub-
strate, precursors, pathway markers, bioactive mediators, and
the further metabolites. Bioactive LM profiling of medium and
lysate samples from IL-1b–stimulated AT and AR cells was
performed using previously described methodology (29). Cali-
brationcurveswereobtained for eachusingauthentic compound
mixtures and deuterium-labeled LM at 0.78, 1.56, 3.12, 6.25, 12.5,
25, 50, 100, and 200 pg. Linear calibration curves were obtained
for each LM, which gave r2 values of 0.98–0.99.
Immunocytochemistry for 15-epi-LXA4 and
MaR1-treated Achilles stromal cells
IL-1b–stimulatedATandAR tendon stromal cellswere grown in
chamber slides and treated as previously described. After in-
cubation in 15-epi-LXA4 or MaR1, cells were fixed in ice-cold
methanol for 5 min and washed with PBS. Immunofluorescence
staining protocols and image acquisition are adapted from a
previously publishedprotocol (23). Tendon stromal cells isolated
from AT and AR donors (n = 3 each) were incubated with the
following primary antibodies: anti-ALX (ab26316; Abcam,
Cambridge,MA,USA), anti–arachidonate lipoxygenase (ALOX)
15 (ab119774; Abcam), anti-ALOX12 (ab211506; Abcam), anti–
Phospho-STAT-1 (ab29045; Abcam), anti-PDPN (ab10288;
Abcam), and anti–IL-6 (ab9324; Abcam) in PBS containing 5%
goat serum in saponin for 3 hat room temperature. For negative
controls, the primary antibody was substituted for universal
isotype control antibodies: cocktail ofmouse IgG1, IgG2a, IgG2b,
IgG3, and IgM (Agilent Technologies, Santa Clara, CA, USA) and
rabbit Ig fraction of serum from nonimmunized rabbits, solid
phase absorbed. Isotype control staining is shown in Supple-
mental Fig. S1. Immunofluorescence images were acquired on a
Zeiss Laser Scanning Microscope (LSM; Carl Zeiss, Oberkochen,
Germany) 710 confocal microscope using a previously described
protocol (23).
Expression of proinflammatory and proresolving
genes in AT and AR tendon stromal cells incubated
in 15-epi-LXA4 or MaR1
ATandAR tendon-derived stromal cells (n=5each)were seeded
at adensity of 20,000 cells perwell in a 24-well plate. Tendon cells
were allowed to reach 80% confluence prior to preincubation
with 15-epi-LXA4 or MaR1 and subsequent stimulation with IL-
1b (10 ng/ml; MilliporeSigma). Nontreated cells (vehicle only,
containing 0.1% endotoxin-free bovine serum albumin; Milli-
poreSigma) served as controls for each experiment. After treat-
ment, cellswere then incubated at 37°Cand5%CO2until harvest
of the cell lysate for mRNA after 24 h. RNA isolation, cDNA
synthesis, and quantitative PCR were performed using pre-
viously published protocols (25). Prevalidated Qiagen (Hilden,
Germany) primer assays [ALOX15, IL-6, STAT-1, CD90, IRF5,
TLR4, b-actin, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)] were used for quantitative PCR. Results were calcu-
lated using the ΔΔCt method using reference genes for human
b-actin and GAPDH. Results were consistent using these refer-
ence genes, and data are shown normalized to b-actin.
Phosphokinase signaling in 15-epi-LXA4 and
MaR1-treated AT tendon stromal cells
A Human Phosphokinase Array Kit (ARY003B; R&D Systems,
Minneapolis, MN, USA) was used to investigate the effects of in-
cubating IL-1b–treated AT cells in 15-epi-LXA4 or MaR1 on pro-
tein phosphokinase signaling pathways. Experimental protocols
were performed according to the manufacturer’s instructions on
protein lysates harvested after 24 h of incubation in either 15-epi-
LXA4 orMaR1. Imageswere capturedusing a chemiluminescence
documentation system (Uvitec, Cambridge, United Kingdom),
and densitometry analysis of proteins of interest was performed
using ImageJ software (National Institutes of Health, Bethesda,
MD, USA).
Statistical analysis
Statistical analyses were performed using GraphPad Prism 7
(GraphPad Software, La Jolla, CA, USA). Normality was tested
using the Shapiro-Wilk normality test. Analysis of bioactive LM
profiles from tendon cells derived frompatientswithATandAR
was performed using multivariate statistical analysis and or-
thogonal partial least squares discriminant analysis using Sta-
tistical Isolinear Multiple Components Analysis (SIMCA) 14.1
software (Sartorius, Go¨ttingen, Germany) following unit vari-
ance scaling of LM amounts. Partial least squares discriminant
analysis is based on a linear multivariate model that identifies
variables that contribute to class separation of observations (cell
incubations) on the basis of their variables (LM levels). During
LM classification, observations were projected onto their re-
spective class model. The score plot illustrates the systematic
clusters among the observations (closer plots presenting higher
similarity in the data matrix). Loading plot interpretation iden-
tified the variables with the best discriminatory power (variable
importance in projection .1) that were associated with tight
clusters forLMprofilesobtained fromincubationswithcells from
patients with AT or AR. Data are shown as means with SEM,
where n is the biologic replicate (human donor of cells derived
from healthy or diseased tendons). Unpaired Student’s t tests
wereused to test fordifferences inLMlevelsbetween tendoncells
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derived from patients with AT and AR. Paired Student’s t tests
were used to test for differences in LM levels after incubating AT
or AR cells in the presence of 15-epi-LXA4 or MaR1 compared
with vehicle control. Pairwise Mann-Whitney U tests were used
to test for differences betweenmRNA expression ofALOX15, IL-
6, STAT-1, CD90, IRF5, and TLR4 in IL-1b–treated tendon stro-
mal cells in the presence or absence of SPMs. Values of P, 0.05
were considered statistically significant.
RESULTS
Stromal cells derived from patients with AT
and AR show distinct LM profiles
LM profiling of tendon-derived stromal cell cultures from
AT and AR patients identified SPMs including D-series
resolvins (RvDs) (RvD1, -2, -3, -4, -5, -6, 17R-RvD1, and
17R-RvD3), protectins [protectin D1 (PD1); 17R-PD1; and
10S,17S–dihydroxydocosahexaenoic acid], MaRs (MaR1,
MaR2), E-series resolvins (RvEs) (RvE2 and RvE3), T-
series resolvins (RvTs) (RvT1 and RvT4), arachidonic
acid–derived lipoxins (LXs) (LXA4, LXB4, 15-epi-LXA4,
and 15-epi-LXB4), and n-3 DPA-derived resolvins
(RvD1n-3 DPA, -2n-3 DPA, and -5n-3 DPA), protectins
(PD1n-3 DPA), and MaRs (MaR1n-3 DPA). These mediators
were identified in accordance with published criteria that
includematching retention times and at least 6 ions in the
tandem mass spectrum (27). Cumulative levels of pro-
resolving mediators did not significantly differ between
AT- andAR-derived cells. However,multivariate analysis
identified differences in the bioactive LMprofiles between
tendon cells derived from AT and AR patients under
baseline unstimulated conditions as demonstrated by the
distinct clustering of the LM profiles (Fig. 1A, B). The
molecules profiled, togetherwith the concentrations of the
individual LMs identified, are listed in Supplemental Ta-
ble S1. Assessment of individual LM concentrations
demonstrated increased levels of 15-epi-LXB4 (P = 0.03) in
AT compared with AR cells (Fig. 1C). In incubations of
AT cells, we also found increases in inflammation-
initiating eicosanoids including prostaglandin (PG) E2
and PGF2a (Supplemental Table S1). This increase in both
SPMs and eicosanoids in tendon-derived stromal cells
from AT patients suggests that, although SPMs are up-
regulated in these cells, their concentrations are not suffi-
cient to counterregulate the ongoing inflammatory
processes, reminiscent of a dysregulated resolution re-
sponse characteristic of chronic inflammation.
LM profiling was also performed on AT and AR cells
after treatment with IL-1b (10 ng/ml) for 24 h to induce
an inflammatory milieu and determine if this cytokine
moderated the release of proresolving mediators and
inflammation-initiating eicosanoids from these cells. Mul-
tivariate analysis for IL-1b–treated AT and AR cells is
shown in Fig. 2A, B. The molecules profiled, together with
the concentrations of the individual LMs identified, are lis-
ted in Supplemental Table S1. In these incubations, IL-1b–
treatedARcells showed increased levels of PGE2 compared
with respective AT cells (P = 0.05, Fig. 2C). The increased
responsiveness of AR cells to cytokine stimulation may re-
flect the acute inflammatory milieu of these cells.
15-Epi-LXA4 and MaR1 induce SPM production
and regulate inflammation-initiating
eicosanoids in Achilles tendon–derived
stromal cells
In order to gain insight into whether SPMs can regulate
tendon stromal cell inflammation, we next tested whether
Figure 1. DistinctbioactiveLMproﬁlesof stromal cells isolated frompatientswithATandAR.Tendonstromal cells (60,000cellsperwell)
were derived from patients with AT (n = 7 donors) or AR (n = 7 donors). Cells were cultured in DMEM F12 phenol red–free medium
containing1%heat-inactivatedhumanserumto80%conﬂuenceand incubated for 24h.Mediumandcellswereharvestedandplaced in
ice-coldmethanol containing deuterium-labeled internal standards. LMwere then extracted and proﬁled.A, B) Two-dimensional (2D)
scoreplot (A) andcorresponding2D loadingplot (B)ofLM-SPMfromhuman tendon–derived stromal cell incubations isolated fromAT
andARpatients under baseline unstimulated conditions. Gray ellipse in the score plot denotes 95%-conﬁdence regions. 13,14-Dehydro-
15-oxo-Lipoxin A4; 22-OH-MaR1, 22-OH-Maresin 1; 22-OH-PD1, 22-OH-Protectin D1; 5S,12S-HETE, 5S,12S–hydroxyeicosatetraenoic
acid; 10S,17S-diHDHA, 10S,17S–dihydroxydocosahexaenoic acid; 10S,17S-diHDPA, 10S,17S–dihydroxydocosapentaenoic acid; TXB2,
thromboxane B2. C) Concentrations for mediators found to be differentially regulated between AT and AR tendon stromal cell
incubations. Results are shown as means and SEM and are representative of n = 7 donors per group.
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incubationof these cellswith15-epi-LXA4orMaR1, 2of the
SPMs identified in Achilles tendon cell incubations, mod-
ulated the bioactive LM profiles of IL-1b–stimulated AT
and AR tendon stromal cells. Multivariate analysis identi-
fied differences in bioactive LM profiles between IL-1b–
stimulated AT cells in the presence of 10 nM 15-epi-LXA4
comparedwith vehicle-only incubations, demonstrated by
the distinct clustering of the LM profiles (Fig. 3A, B). The
molecules profiled, together with the concentrations of the
individual LMs identified, are listed in Supplemental Table
S2. Incubation of IL-1b–stimulatedAT cells in 15-epi-LXA4
significantly regulated inflammation-initiating eicosanoids
including PGE2, PGF2a, and thromboxane B2 (Fig. 3C, P =
0.03). We also found that incubating AT cells in 15-epi-
LXA4 up-regulated production of proresolving mediators
and significantly increased RvD4 (P = 0.04) and PGD2 (P =
0.025) compared with respective vehicle controls (Fig. 3C
and Supplemental Table S2). Assessment of LM profiles
from IL-1b–stimulated AR cells incubated with 10 nM 15-
epi-LXA4 compared with vehicle-only incubations dem-
onstrated distinct clustering of the LMprofiles (Fig. 3D, E).
Themolecules profiled, togetherwith the concentrations of
the individual LMs identified, are listed in Supplemental
TableS2. Incubationof IL-1b–stimulatedARcells in15-epi-
LXA4 regulated all inflammation-initiating eicosanoids
(P=0.01), specificallydecreasingPGE2 (P=0.03)andPGF2a
(P = 0.02) (Fig. 3F and Supplemental Table S2). We also
found that incubating AR cells in 15-epi-LXA4 induced
production of all proresolving mediators compared with
respective vehicle controls (Fig. 3F).
We next investigated whether incubation of AT cells
with MaR1 altered LM profiles in response to IL-1b stim-
ulation. Multivariate analysis demonstrated that MaR1
incubation led to a shift in the bioactive LM profiles of
IL-1b–stimulated AT cells compared with vehicle-only
incubations (Fig. 4A, B). The molecules profiled, together
with the concentrations of the individual LMs identified,
are listed in Supplemental Table S2. Incubation of IL-1b–
stimulated AT cells with MaR1 dampened inflammation-
initiating eicosanoids and induced release of proresolving
mediators (Fig. 4C). This treatment increased specific
SPMs including 15-epi-LXA4 (P= 0.002), RvD4 (P= 0.005),
and theMaRmetabolite 14-oxo-MaR1 (P=0.03) compared
with respectivevehicle controls (Fig. 4CandSupplemental
Table S2).
MaR1 incubation also resulted in a shift in the LM
profile of AR cells, as demonstrated by a separation in the
LM clusters obtained in orthogonal partial least squares
discriminant analysis (Fig. 4D, E). Themolecules profiled,
together with the concentrations of the individual LMs
identified, are listed in Supplemental Table S2. Incubation
of IL-1b–stimulated AR cells with MaR1 regulated all
inflammation-initiating eicosanoids (P = 0.01), specifically
decreasing PGE2 (P= 0.04) (Fig. 4F). IncubatingAR cells in
MaR1 also increased the production of all proresolving
mediators (P = 0.04). This treatment increased specific
SPMs including 17R-RvD3 (P = 0.05) and the MaR me-
tabolite 14-oxo-MaR1 (P = 0.05) comparedwith respective
vehicle controls (Fig. 4F). Together, these findings dem-
onstrate that 15-epi-LXA4 and MaR1 counterregulate IL-
1b–initiated inflammation in tendon stromal cells derived
from patients with AT and AR.
15-Epi-LXA4 and MaR1 up-regulate the
expression of SPM biosynthetic enzymes
and proresolving receptor ALX in
Achilles tendon stromal cells
We next investigated the mechanisms by which 15-epi-
LXA4 and MaR1 potentiated release of proresolving
Figure 2. Distinct bioactive LM proﬁles of IL-1b–stimulated stromal cells isolated from patients with AT and AR. Tendon stromal
cells (60,000 cells per well) were derived from patients with AT (n = 9 donors) or AR (n = 9 donors). Cells were cultured in
DMEM F12 phenol red–free medium containing 1% heat-inactivated human serum to 80% conﬂuence and incubated for 24 h in
the presence of IL-1b (10 ng/ml). Medium and cells were harvested and placed in ice-cold methanol containing deuterium-
labeled internal standards. A, B) LM were then extracted and proﬁled. Two-dimensional (2D) score plot (A) and corresponding
2D loading plot (B) of LM-SPM from human tendon–derived stromal cell incubations isolated from AT and AR patients under
IL-1b–stimulated conditions. Gray ellipse in the score plot denotes 95%-conﬁdence regions. 13,14-Dehydro-15-oxo-Lipoxin A4;
22-OH-MaR1, 22-OH-Maresin 1; 22-OH-PD1, 22-OH-Protectin D1; 5S,12S-HETE, 5S,12S–hydroxyeicosatetraenoic acid; 10S,17S-
diHDHA, 10S,17S–dihydroxydocosahexaenoic acid; 10S,17S-diHDPA, 10S,17S–dihydroxydocosapentaenoic acid; TXB2, throm-
boxane B2. C) Concentrations for mediators found to be differentially regulated between IL-1b–stimulated AT and AR tendon
stromal cell incubations. Results are shown as means and SEM and are representative of n = 9 donors per group.
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mediators. Incubation of IL-1b–stimulated AT or AR cells
in 15-epi-LXA4 induced expression of ALOX15 mRNA
relative to IL-1b–stimulated vehicle controls (P = 0.01 and
P = 0.03, respectively; Fig. 5A). Incubation of IL-1b–
stimulated AT or AR cells in 15-epi-LXA4 or MaR1
induced ALOX12 and ALOX15 when compared with re-
spective vehicle controls (Fig. 5B). We next investigated
whether these SPMs also up-regulated the expression of
the proresolving receptor ALX, given its role in the ter-
mination ofmusculoskeletal inflammation (30, 31). Indeed
Figure 3. 15-Epi-LXA4 in-
duces SPMs and dampens
inﬂammation-initiating eicos-
anoids in IL-1b–stimulated
stromal cells isolated from
patients with AT and AR.
Tendon stromal cells were
derived from patients with
AT (n = 5 donors) or AR
(n = 5 donors). Cells were
incubated with 15-epi-LXA4
(10 nM) or vehicle for 24 h at
37°C and then with IL-1b (10
ng/ml) for 24 h. LMs were
identiﬁed and quantiﬁed us-
ing LM proﬁling. A, B) Two-
dimensional (2D) score plot
(A) and corresponding 2D
loading plot (B) of LM-SPM
from human tendon–derived
stromal cell incubations iso-
lated from AT patients under
IL-1b–stimulated conditions
in the presence of 10 nM 15-
epi-LXA4 or vehicle only. C)





Protectin, MaR, n-3 DPA-de-
rived RvDn-3 DPA, PDn-3 DPA,
MaR1n-3 DPA, eicosapentaenoic
acid–derived RvE, and arachi-
donic acid-derived LX), and
differentially regulated LMs in
IL-1b–stimulated AT tendon
stromal cell incubations in the
presence of 15-epi-LXA4 (10
nM) or vehicle for 24 h.
Results are shown as means
and SEM and are representa-
tive of n = 5 donors per group.
D, E) The 2D score plot
(D) and corresponding 2D
loading plot (E) of plasma
LM-SPM from human tendon–
derived stromal cell incuba-
tions isolated from AR patients
under IL-1b–stimulated condi-
tions in the presence of 10
nM 15-epi-LXA4 or vehicle




LMs in IL-1b–stimulated AR
tendon stromal cell incuba-
tions in the presence of 15-
epi-LXA4 (10 nM) or vehicle
for 24 h. 13,14-Dehydro-15-oxo-Lipoxin A4; 22-OH-MaR1, 22-OH-Maresin 1; 22-OH-PD1, 22-OH-Protectin D1; TXB2, thromboxane
B2. Results are shown as means and SEM and are representative of n = 5 donors per group.
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Figure 4. MaR1 induces SPM and dampens inﬂammation-initiating eicosanoids in IL-1b–stimulated stromal cells isolated from
patients with AT and AR. Tendon stromal cells were derived from patients with AT (n = 5 donors) or AR (n = 5 donors). Cells were
incubated with MaR1 (10 nM) or vehicle for 24 h at 37°C and then with IL-1b (10 ng/ml) for 24 h. LMs were identiﬁed and
quantiﬁed using LM proﬁling. A, B) Two-dimensional (2D) score plot (A) and corresponding 2D loading plot (B) of LM-SPM from
human tendon–derived stromal cell incubations isolated from AT patients under IL-1b–stimulated conditions in the presence of
10 nM MaR1 or vehicle only. C) Cumulative levels of inﬂammation-initiating eicosanoids, proresolving mediators, and differentially
regulated proresolving mediators in IL-1b–stimulated AT tendon stromal cell incubations in the presence of MaR1 (10 nM) or
vehicle for 24 h. Results are shown as means and SEM and are representative of n = 5 donors per group. D, E) A 2D score plot (D)
and corresponding 2D loading plot (E) of plasma LM-SPM from human tendon–derived stromal cell incubations isolated from AR
patients under IL-1b–stimulated conditions in the presence of 10 nM MaR1 or vehicle only. F) Cumulative levels of inﬂammation-
initiating eicosanoids, proresolving mediators, and differentially regulated LMs in IL-1b–stimulated AR tendon stromal cell
incubations in the presence of MaR1(10 nM) or vehicle for 24 h. 13,14-Dehydro-15-oxo-Lipoxin A4; 22-OH-MaR1, 22-OH-Maresin
1; 22-OH-PD1, 22-OH-Protectin D1; TXB2, thromboxane B2. Results are shown as means and SEM and are representative of n = 5
donors per group.
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both 15-epi-LXA4 and MaR1 up-regulated the expression
of this receptor in both AT and AR cells, with a marked
increase observed in AT cells.
15-Epi-LXA4 and MaR1 moderate the
inflammatory phenotype of Achilles tendon
stromal cells, dampening proinflammatory
signaling pathways
We next assessed whether 15-epi-LXA4 and MaR1
also regulated knownmarkers of tendon inflammation in
patient-derived AT and AR cells. Incubation of IL-1b–
stimulated AT and AR cells in 15-epi-LXA4 or MaR1
reduced fibroblast activation marker PDPN, phosphory-
lated STAT-1, and IL-6 after 24 h of incubation compared
with respective vehicle controls (Fig. 6A, B). In IL-1b–
stimulated AT cells, 15-epi-LXA4 reduced IL-6, STAT-1,
CD90, IRF5, and TLR4mRNA expression comparedwith
vehicle control–treated cells (P=0.008,P=0.02,P=0.03,P
= 0.02, and P = 0.008, respectively; Fig. 6C). Incubating IL-
1b–stimulated AT cells in MaR1 reduced STAT-1, IRF5,
and TLR4 mRNA compared with vehicle controls (P =
0.008,P= 0.04, andP= 0.03, respectively; Fig. 6C). In these
incubations, 15-epi-LXA4 or MaR1 regulated phosphoki-
nases including c-Jun N-terminal kinase (JNK)1/2/3
(phosphorylation sites T183/Y185, T221/Y223), Lyn
(Y397), STAT-3 (Y705), and STAT-6 (Y641) compared
with respective vehicle control–treated cells (Fig. 6D).
DISCUSSION
Tissue-resident stromal cells including fibroblasts are
emerging as important cell types sustaining chronic
Figure 5. 15-Epi-LXA4 and MaR1 induce SPM
synthetic enzymes and ALX in Achilles tendon
stromal cells. Tendon stromal cells were de-
rived from patients with AT (n = 5 donors) or
AR (n = 5 donors). Cells were incubated with
15-epi-LXA4 (10 nM) or vehicle for 24 h at
37°C and then with IL-1b (10 ng/ml) for 24 h.
A) Incubation in 15-epi-LXA4 signiﬁcantly
induced ALOX15 mRNA in both AT (P =
0.01) and AR (P = 0.03) cells compared with
respective vehicle controls. Gene expression is
normalized to b-actin; bars show median
values. B) Representative images of immuno-
cytochemistry for the proresolving receptor
ALX (green) and SPM synthetic enzymes
ALOX12 (violet) and ALOX15 (red) in IL-
1b–stimulated AT and AR tendon stromal cells
incubated in 10 nM 15-epi-LXA4, 10 nM MaR1,
or vehicle control for 24 h. Cyan represents
Popo-1 nuclear counterstain. All images are
representative of n = 3 donors. Scale bar,
20 mm.
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Figure 6. 15-Epi-LXA4 and MaR1 moderate the proinﬂammatory phenotype of Achilles tendon stromal cells. Tendon stromal
cells were derived from patients with AT or AR. A, B) Representative images of immunocytochemistry for established markers of
tendon inﬂammation including PDPN (green), phosphorylated STAT-1 (green), and IL-6 (red) in IL-1b–stimulated AT (A) and
AR (B) tendon stromal cells incubated in 10 nM 15-epi-LXA4, 10 nM MaR1, or vehicle control for 24 h. Cyan represents Popo-1
nuclear counterstain. All images are representative of n = 3 donors. Scale bars, 20 mm. C) mRNA expression of markers of tendon
inﬂammation including IL-6, STAT-1, pathogenic ﬁbroblast marker CD90, IRF5, and TLR4 in IL-1b–stimulated AT cells (n = 5
(continued on next page)
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inflammation in common soft tissue diseases of the joint
(32). Tendon fibroblasts are implicated in thedevelopment
of chronic inflammation through stromal fibroblast acti-
vation and inflammation memory (22, 26). We previously
identified bioactive LM profiles in tendon stromal cells
derived from patients with shoulder tendon tears, identi-
fying dysregulated resolution responses in cells isolated
from diseased compared with healthy donors (23). In the
current study, we investigated whether tendon stromal
cells derived from AT and AR patients showed distinct
bioactive LM profiles. AT and AR both represent clinical
manifestations of established tendon disease. Although
ARpatientsmay have established tendon pathology prior
to rupture, the episode of recent traumatic injury associ-
ated with the event of tendon rupture presents a super-
imposed phase of acute inflammation on an already
chronically inflamed tendon (22). Using tendon stromal
cells isolated from fresh patient tissues, we identified dif-
ferences in bioactive LM profiles between AT and AR
tendon stromal cells under baseline unstimulated condi-
tions. AT cells showed significantly increased levels of 15-
epi-LXB4 compared with AR cells. AT cells also showed
increased levels of inflammation-initiating eicosanoids
PGE2 and PGF2a compared with AR cells. These find-
ings suggest that, although SPMs are up-regulated in
AT-derived stromal cells, their concentrations are not suf-
ficient to counterregulate the ongoing inflammatory pro-
cess, which is reminiscent of the dysregulated resolution
responses we previously identified in shoulder tendon
tears (23). We subsequently stimulated AT and AR cells
with IL-1b because it is known to induce expression ofNF-
kB target genes highly expressed in human tendon disease
(22, 25), therefore recapitulating an inflammatory milieu.
In these incubations, we found increased PGE2 levels in
AR compared with respective AT cells. This increased
responsiveness of AR cells may be attributable to the
acute inflammatory milieu associated with traumatic AR,
whereby cells are “primed” as a consequence of a recent
episode of acute inflammation. Therefore, the differences
in the bioactive LMprofiles betweenAT andAR cells may
reflect the temporal effects of disease stage associatedwith
different clinicalmanifestations ofAchilles tendondisease.
Previous studies have identified temporal release of SPMs
during the resolution phase of inflammatory responses. A
study utilizing self-limiting exudates identified a distinct
time frame of the proresolving mediator RvD3, which
appeared late in the resolution phase (33). MaR1 was also
shown to be temporally regulated in Escherichia coli leu-
kocyte infectious exudates (34). In the current study of
patient tissue samples, it was not possible to obtain se-
quential tendon biopsies, prohibiting the study of tem-
poral metabolipidomics within individual patients.
Having identified that a select group of proresolving
mediators were released by patient-derived Achilles ten-
don cells,we next investigated the biologic actions of these
autacoids, and their capacity to regulatemolecular aspects
of inflammation in AT and AR. Incubating IL-1b–
stimulated AT or AR cells in 15-epi-LXA4 or MaR1
regulated inflammation-initiating eicosanoids and up-
regulated concentrations of SPMs in these incubations.We
previously identified these SPM-induced analogous re-
sponses in tendon stromal cells isolated frompatients with
shoulder tendon tears, and we showed that the effects of
these SPMswereblunted inpatient comparedwithhealthy
volunteer tendon-derived stromal cells (23). We also
identified the MaR1 metabolite 14-oxo-MaR1 in MaR1-
incubated cells isolated from shoulder tendon tear patients
(23). The current study confirmed the presence of this
metabolite inMaR1-incubatedATandARcells, suggesting
that common shared mechanisms exist for MaR1 metabo-
lism in stromal fibroblasts isolated from positional shoul-
der and energy-storing Achilles tendons. In the current
study, incubation in 15-epi-LXA4 specifically up-
regulated RvD4 and PGD2 in IL-1b–stimulated AT cells.
Conversely, incubation with MaR1 induced 15-epi-LXA4
andRvD4 inATcells and17-R-RvD3 inARcells.Although
15-epi-LXA4 and MaR1 up-regulated concentrations of
specific SPMs in these incubations, both treatments re-
duced known markers of tendon inflammation, including
IL-6, STAT-1, and fibroblast activation markers CD90
and PDPN, which are associated with disease severity
(22, 25, 26). Collectively, these findings suggest that
incubation of IL-1b–stimulated AT and AR tendon-
derived stromal cells in 15-epi-LXA4 or MaR1 regulate
inflammation-initiating eicosanoids, potentiate the re-
lease of proresolving mediators, and moderate the
proinflammatory phenotype of these patient-derived
cells.
We next investigated the mechanism of action un-
derpinning these observations. Incubation of AT and AR
cells in either15-epi-LXA4orMaR1 inducedSPMsynthetic
enzymes ALOX12 and ALOX15 and the proresolving re-
ceptorALX. 15-Epi-LXA4 alsoprofoundly inducedALX in
IL-1b–stimulated AT cells. We also identified incubation
of IL-1b–stimulated AT cells in 15-epi-LXA4– or MaR1-
regulated phosphokinases including JNK1/2/3, Lyn,
STAT-3, and STAT-6. Binding of 15-epi-LXA4 to ALX is
known to suppress kinases downstream of MAPK, in-
cluding JNK (35). The findings fromour study suggest that
15-epi-LXA4 orMaR1 regulate IL-6 via suppressing STAT-
3 signaling in AT stromal cells. Suppression of STAT-6
signaling may modulate IL-4 and IL-13 responsive genes
known to drive fibrosis in the advanced stages of tendon
disease (25, 36). Lyn is an Src family kinase regulating
multiple aspects of immune signaling (37, 38). Ban et al.
(39) recently identified Lyn as a specific suppressor of the
TLR–myeloid differentiation primary response 88–IRF5
pathway, highlighting the importance of this kinase in
regulating IRF5 activity in immune homeostasis in Sys-
temic Lupus Erythematosus. We previously identified
donors) incubated in either 10 nM 15-epi-LXA4, 10 nM MaR1, or vehicle control for 24 h. Gene expression is normalized to
b-actin, and bars show median values. D) Densitometric analysis was acquired using ImageJ software to identify the effects of
incubating IL-1b–treated AT cells in 15-epi-LXA4 or MaR1 on protein phosphokinase signaling pathways JNK1/2/3, Lyn, STAT3,
and STAT6. Results are shown as means and SEM and are representative of n = 3 donors per group relative to respective vehicle
control–treated cells.
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IRF5 and TLR4 as being highly expressed in tissues from
patients with AT and AR (22). In the current study, in-
cubation of IL-1b–stimulated AT cells in 15-epi-LXA4 or
MaR1 suppressed IRF5 and TLR4 mRNA expression
comparedwithvehicle control–treatedcells. Therefore, 15-
epi-LXA4– or MaR1-induced regulation of Lyn presents a
potentialmeans of regulating proinflammatorymolecules
including IRF5 and TLR4 in Achilles tendon disease.
It was not possible to determine the anti-inflammatory
medications receivedbyARpatients in this study.Of note,
in the event that these patients had taken NSAIDs, it is
unlikely that these will have a significant impact on the
biosynthesis of LMs by cells in culture because these
therapeutics are anticipated to be diluted out in culture. In
addition, for those anti-inflammatories that irreversibly
bind to and inhibit their target enzymes, such as aspirin,
the target protein is likely turned over in culture and,
therefore, the activity of these drugs is lost.
In summary, we identified some differences in bio-
active LM profiles between tendon stromal cells isolated
from patients with AT and AR, which likely reflect the
temporal effects of disease stage. We demonstrate that
15-epi-LXA4 and MaR1 regulate expression of proin-
flammatory molecules including PGE2, PDPN, CD90,
STAT-1, IL-6, IRF5, and TLR4 and dampen phosphoki-
nases including JNK1/2/3, Lyn, STAT-3, and STAT-6.
These SPMs also up-regulated proresolving mediators in
IL-1b–stimulated AT and AR cells. Collectively, these
findings suggest that 15-epi-LXA4 and MaR1 are poten-
tial future therapies to counterregulate inflammatory
processes in cells isolated from patients with AT and
AR.
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